ARTICLE | Product Development
U.S. limits distribution of Lilly-AbCellera COVID-19 mAb over concerns it is ineffective against variant
March 17, 2021 11:44 PM UTC
The U.S. government is limiting distribution in California, Arizona, and Nevada of bamlanivimab, a COVID-19 mAb manufactured by Eli Lilly, because of concerns about its efficacy in treating disease caused by a SARS-CoV-2 variant circulating in those states.
The action does not affect the two other COVID-19 mAb therapies with emergency use authorization in the U.S.: the bamlanivimab/etesevimab combination from Eli Lilly and Co. (NYSE:LLY) and the casirivimab/imdevimab cocktail from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). ...